Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JWATM214 (JW Therapeutics)
- Development stage
- Preclinical
- Lead developer
- JW Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JWATM214 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by JW Therapeutics for the treatment of small cell lung cancer (SCLC). The therapy is engineered to target the melanoma-associated antigen A4 (MAGE-A4), a cancer-testis antigen that is frequently overexpressed in various solid tumors but has highly restricted expression in normal tissues. By expressing a CAR specific to MAGE-A4, the patient's own T cells are redirected to recognize and eliminate malignant cells expressing this antigen. As of early 2024, JWATM214 is in the preclinical stage of development, representing part of JW Therapeutics' expansion into cell therapies for solid tumor indications.
- Other names
- MAGE-A4 CAR-TMAGE-A-4 CAR-TMAGE-A 4 CAR-T
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on JWATM214 (JW Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JWATM214 (JW Therapeutics).